<?xml version='1.0' encoding='utf-8'?>
<document id="21625418"><sentence text="Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus."><entity charOffset="9-21" id="DDI-PubMed.21625418.s1.e0" text="pitavastatin" /></sentence><sentence text="Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, known as statins, have revolutionized the treatment of hypercholesterolemia and coronary artery disease prevention" /><sentence text=" However, there are considerable issues regarding statin safety and further development of residual risk control, particularly for diabetic and metabolic syndrome patients" /><sentence text=" Pitavastatin is a potent statin with low-density lipoprotein (LDL) cholesterol-lowering effects comparable to those of atorvastatin or rosuvastatin"><entity charOffset="1-13" id="DDI-PubMed.21625418.s4.e0" text="Pitavastatin" /><entity charOffset="68-79" id="DDI-PubMed.21625418.s4.e1" text="cholesterol" /><entity charOffset="120-132" id="DDI-PubMed.21625418.s4.e2" text="atorvastatin" /><entity charOffset="136-148" id="DDI-PubMed.21625418.s4.e3" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.21625418.s4.e0" e2="DDI-PubMed.21625418.s4.e0" /><pair ddi="false" e1="DDI-PubMed.21625418.s4.e0" e2="DDI-PubMed.21625418.s4.e1" /><pair ddi="false" e1="DDI-PubMed.21625418.s4.e0" e2="DDI-PubMed.21625418.s4.e2" /><pair ddi="false" e1="DDI-PubMed.21625418.s4.e0" e2="DDI-PubMed.21625418.s4.e3" /><pair ddi="false" e1="DDI-PubMed.21625418.s4.e1" e2="DDI-PubMed.21625418.s4.e1" /><pair ddi="false" e1="DDI-PubMed.21625418.s4.e1" e2="DDI-PubMed.21625418.s4.e2" /><pair ddi="false" e1="DDI-PubMed.21625418.s4.e1" e2="DDI-PubMed.21625418.s4.e3" /><pair ddi="false" e1="DDI-PubMed.21625418.s4.e2" e2="DDI-PubMed.21625418.s4.e2" /><pair ddi="false" e1="DDI-PubMed.21625418.s4.e2" e2="DDI-PubMed.21625418.s4.e3" /></sentence><sentence text=" Pitavastatin has a high-density lipoprotein (HDL) cholesterol raising effect, may improve insulin resistance, and has little influence on glucose metabolism"><entity charOffset="1-13" id="DDI-PubMed.21625418.s5.e0" text="Pitavastatin" /><entity charOffset="51-62" id="DDI-PubMed.21625418.s5.e1" text="cholesterol" /><entity charOffset="139-146" id="DDI-PubMed.21625418.s5.e2" text="glucose" /><pair ddi="false" e1="DDI-PubMed.21625418.s5.e0" e2="DDI-PubMed.21625418.s5.e0" /><pair ddi="false" e1="DDI-PubMed.21625418.s5.e0" e2="DDI-PubMed.21625418.s5.e1" /><pair ddi="false" e1="DDI-PubMed.21625418.s5.e0" e2="DDI-PubMed.21625418.s5.e2" /><pair ddi="false" e1="DDI-PubMed.21625418.s5.e1" e2="DDI-PubMed.21625418.s5.e1" /><pair ddi="false" e1="DDI-PubMed.21625418.s5.e1" e2="DDI-PubMed.21625418.s5.e2" /></sentence><sentence text=" Considering these factors along with its unique pharmacokinetic properties, which suggest minimal drug-drug interaction, pitavastatin could provide an alternative treatment choice, especially in patients with glucose intolerance or diabetes mellitus"><entity charOffset="122-134" id="DDI-PubMed.21625418.s6.e0" text="pitavastatin" /><entity charOffset="210-217" id="DDI-PubMed.21625418.s6.e1" text="glucose" /><pair ddi="false" e1="DDI-PubMed.21625418.s6.e0" e2="DDI-PubMed.21625418.s6.e0" /><pair ddi="false" e1="DDI-PubMed.21625418.s6.e0" e2="DDI-PubMed.21625418.s6.e1" /></sentence><sentence text=" Many clinical trials are now underway to test the clinical efficacy of pitavastatin in various settings and are expected to provide further information"><entity charOffset="72-84" id="DDI-PubMed.21625418.s7.e0" text="pitavastatin" /></sentence><sentence text="" /></document>